IAVI Report

Coalition awards US$174 million in grants for research targeting Nipah virus, Lassa fever, and MERS.

The vaccine world lost another of its great leaders recently with the passing of Adel Mahmoud, a physician, scientist, and professor who played a critical role in the development of many innovative and lifesaving vaccines during his long and successful career. He is remembered by his friends and colleagues as a tireless champion of public…

The pandemic isn’t over, but that might be what donors are hearing.

In a few weeks, the AIDS 2018 meeting will kick off in Amsterdam. It will be the 22nd annual conference, and remains the largest international gathering focused on a single public health issue. This year, one message that will come out loud and clear is that more than 30 years later, AIDS isn’t over. As…

Marianne Mureithi is part of a team of researchers that just received highly competitive funding to study mucosal immune responses to HIV in Kenya.

Drone delivery may help overcome the challenge of getting medicines and vaccines to hard-to-reach populations.

Maria Grazia Pau, senior director, compound development team leader for HIV vaccine programs at the Janssen Pharmaceutical Companies of Johnson & Johnson, talks with IAVI Report about the start of the company’s Phase III Mosaico trial.

Over hundreds of years, researchers have matched contemporary scientific tools to address the infectious disease threats of their times.

A slew of potential advances in treating and preventing tuberculosis offers new hope in the battle against one of the oldest human afflictions.

Regulatory approval of a vesicular stomatitis virus-based vaccine paves the way for use of this viral vector in other vaccines.

Africa is contributing far more than samples to scientific research. The continent’s scientists are actively engaged in developing and testing novel HIV vaccine candidates.

A conversation with Anatoli Kamali and Penny Moore about the rise of HIV vaccine science in Africa